SÃO PAULO — Brazil's health regulator has approved Indian drugmaker Dr Reddy's Laboratories to sell a generic version of Novo Nordisk's blockbuster diabetes drug Ozempic, the company said on Thursday, 5 November 2026, adding another low-cost rival to a Brazilian market where the Danish drugmaker is already losing ground.
The approval from Brazil's National Health Surveillance Agency, known as Anvisa, covers generic semaglutide — the active ingredient in Ozempic and in Novo Nordisk's weight-loss drug Wegovy — for adults whose type 2 diabetes is not sufficiently controlled, alongside diet and exercise. The once-weekly drug will be sold in 2 mg and 4 mg doses in a pre-filled injector pen, according to Reuters.
Illustration: A pharmacist holds up a generic semaglutide injection pen in a Brazilian pharmacy.
What Happened
Dr Reddy's said on Thursday that Anvisa had authorised it to market and sell the generic semaglutide pen in Brazil. The approval comes seven months after the regulator denied the company's first application in April, when it found the submission did not meet all regulatory requirements, Reuters reported.
The company did not disclose a launch date or a price for the Brazilian market in its announcement. But the approval lands in a market that has become the world's most closely watched test of life after Ozempic's patent protection: Brazil is home to 16.6 million adults aged between 20 and 79 living with diabetes, and ranks sixth globally in the number of adults living with the disease, Dr Reddy's said.
Dr Reddy's has been counting on generic versions of semaglutide as a major growth driver in India and a handful of global markets, Reuters reported. The Brazilian approval is the latest step in that strategy — and it comes with a cautionary note from the company's own recent history. Dr Reddy's recalled batches of generic semaglutide in Canada earlier this year after it found an impurity in the active ingredient, and it said it will relaunch the drug in Canada this quarter, while targeting launches in Latin America and Africa in the coming months.
The new approval also deepens a competitive squeeze that Novo Nordisk itself acknowledged this week. The Danish company is losing market share in Brazil after its semaglutide patent expired, a decline that helped drive a 3 percent fall in emerging market sales in the third quarter, chief executive Mike Doustdar told Reuters on Wednesday, 4 November, after Novo reported third-quarter results that beat forecasts.
"In Brazil, it's really about price, price, price, and a lot of players there," Doustdar said in an interview. "We are actually struggling a bit in that big market and have lost share."
Background
Semaglutide lost patent protection in Brazil in March this year, opening Latin America's largest drug market to cheaper copies. The patent also lapsed in Canada in January and in India in March, according to Reuters, but Brazil has become the sharpest example of what follows when a blockbuster loses exclusivity: multiple generic makers racing in at once, and prices — rather than brand loyalty — deciding who wins.
The first generic semaglutide pen in Brazil was approved in May, when Anvisa cleared Ozivy, a synthetic semaglutide injector pen from Brazilian drugmaker EMS. That drug is produced at an EMS plant in São Paulo state with capacity for up to 40 million pens a year, and it was expected to launch at a price roughly 30 percent below Ozempic, according to reporting at the time. Five other synthetic semaglutide applications and one biological version were under review by Anvisa, Reuters reported in May, and rival Hypera had also said it planned to launch its own generic version this year.
Illustration: People with type 2 diabetes collect medicine at a pharmacy counter in Brazil.
The March patent expiry was settled long before it arrived. Brazil's Superior Court of Justice unanimously denied a legal bid by Novo Nordisk to extend its exclusive patent rights in February 2024, locking in the March 2026 expiration date, according to reporting at the time. That ruling gave generic makers two years to prepare — and they have used them.
The picture has been different elsewhere. In Canada, where patent protection lapsed in January, generic makers ran into supply problems and delays, Doustdar said, and Novo has largely held its ground. In India, where protection ended in March, Novo has also held up so far. But Doustdar warned that the calm in Canada may not last: "It could be that it gets a bit more stormy," he said.
For Dr Reddy's, Brazil is the next front in a global generic semaglutide push that has already hit setbacks. The Canadian recall earlier this year — batches withdrawn after an impurity was found in the active ingredient — showed how closely regulators and rivals are watching the quality of copycat versions of a complex drug. The company's planned relaunch in Canada this quarter will be its chance to show the problem is fixed.
Why It Matters
The approval matters first for the 16.6 million Brazilians living with diabetes. Ozempic and its sister drug Wegovy transformed diabetes and obesity treatment, but their prices put them out of reach for most patients in middle-income countries. Every generic approval pushes prices down — Ozivy's reported launch price, about 30 percent below Ozempic, is only the first step in a market where several rivals are now competing — and wider affordability is the main prize for public health.
It matters second because Brazil is a preview of what is coming for Novo Nordisk worldwide. The company's patents are expiring market by market, and Brazil shows how fast share can slip once cheaper copies arrive. Novo's third-quarter results beat forecasts, and sales in Europe and Canada combined grew 19 percent in the three months, according to Reuters — but the 3 percent decline in emerging market sales, driven by Brazil, shows the cost of the patent cliff in the markets where the company had been counting on growth.
Illustration: Competing diabetes medicines line a pharmacy shelf as price tags signal a new era of competition in Brazil.
It matters third as a test of generic quality. Semaglutide is a complex molecule, and the Canadian impurity recall is a reminder that cheaper does not automatically mean equivalent. Regulators in Brazil, Canada and India are now the gatekeepers for a wave of copycat versions, and their decisions — Anvisa's April rejection of Dr Reddy's first application, followed by Thursday's approval — show that the bar for entry is real. Patients and doctors will be watching whether the new generics perform as well as the original in everyday use.
Finally, it matters for the global access debate. Dr Reddy's says it is targeting launches in Latin America and Africa in the coming months, and its tentative US Food and Drug Administration approval for a generic version of the HIV prevention drug lenacapavir — priced at a reported 40 dollars a year for low- and middle-income countries — shows the same low-cost playbook being applied across diseases. Brazil's generic semaglutide race is the most visible example of a model that could reshape drug prices far beyond one country.
What Happens Next
Dr Reddy's has not yet said when its generic semaglutide pen will reach Brazilian pharmacies or what it will cost. As with earlier generic entrants, pricing approval and distribution deals will shape how quickly the pen gets onto shelves — and how much cheaper it is than Ozempic when it does.
Novo Nordisk's response will also be watched. The company has so far held its ground in Canada and India, where generic makers have faced supply problems, but Doustdar's warning that Canada "could get a bit more stormy" suggests the Danish drugmaker expects the pressure to spread. Whether Novo cuts prices, leans on its brand, or leans on newer products to defend its position will shape the next phase of the contest.
In Canada, Dr Reddy's planned relaunch of its generic semaglutide this quarter will be an early test of whether the impurity problem that forced the recall is fully resolved. A clean relaunch would strengthen the company's case with regulators elsewhere; another setback would hand its rivals — and Novo — a talking point.
More approvals are likely on the way. With five other synthetic semaglutide applications and one biological version under review by Anvisa as of May, according to Reuters, Brazil's generic field is set to get more crowded still. For the millions of Brazilians living with diabetes, that competition is the point: each new approval is another step toward a version of this treatment they can actually afford.
Sponsored: explore today's featured sponsored offers
FAQ
What did Brazil approve on 5 November 2026?
Brazil's health regulator, Anvisa, approved Dr Reddy's Laboratories to market and sell a generic version of Novo Nordisk's diabetes drug Ozempic — generic semaglutide — for adults with insufficiently controlled type 2 diabetes, alongside diet and exercise, according to Reuters.
Why was Dr Reddy's first application rejected?
Anvisa denied approval for the drug in April because the company's application failed to meet all regulatory requirements, Reuters reported. The company reapplied, and the approval announced on 5 November 2026 followed that rejection.
How is the generic drug sold?
The once-weekly drug will be available in 2 mg and 4 mg doses in a pre-filled injector pen, according to Reuters. Dr Reddy's has not yet announced a launch date or a price for the Brazilian market.
Why is Novo Nordisk losing share in Brazil?
Semaglutide lost patent protection in Brazil in March 2026, opening the market to cheaper copies. Novo Nordisk chief executive Mike Doustdar told Reuters on 4 November that the company is losing share in Brazil, saying "it's really about price, price, price, and a lot of players there." The decline helped drive a 3 percent fall in Novo's emerging market sales in the third quarter.
Was Dr Reddy's the first generic semaglutide in Brazil?
No. Brazil's first generic semaglutide pen was Ozivy, from Brazilian drugmaker EMS, approved by Anvisa in May 2026. Dr Reddy's is the latest entrant in a growing field: five other synthetic semaglutide applications and one biological version were under review by Anvisa as of May, according to Reuters.
Sources
- Reuters, 5 November 2026 — "Indian drugmaker Dr Reddy's gets Brazil regulator nod to sell generic Ozempic" (Anvisa approval announced Thursday; generic semaglutide for adults with insufficiently controlled type 2 diabetes alongside diet and exercise; April denial because the application failed to meet all regulatory requirements; once-weekly, 2 mg and 4 mg doses in a pre-filled injector pen; Brazil has 16.6 million adults aged 20–79 living with diabetes and ranks sixth globally, per Dr Reddy's; generic semaglutide a major growth driver for Dr Reddy's in India and a few global markets; Canadian recall earlier in 2026 after an impurity was found in the active ingredient; relaunch in Canada this quarter; launches targeted in Latin America and Africa in the coming months).
- Reuters, 4 November 2026 — "Novo loses share in Brazil to cheaper generics, but holds up in Canada and India" (semaglutide patent expired in Brazil in March 2026; 3 percent decline in emerging market sales in the third quarter; chief executive Mike Doustdar: "In Brazil, it's really about price, price, price, and a lot of players there" and "We are actually struggling a bit in that big market and have lost share"; patent lapsed in Canada in January and in India in March; generic makers faced supply problems and delays in Canada; Doustdar warned "it could be that it gets a bit more stormy"; third-quarter results above forecasts; sales in Europe and Canada combined grew 19 percent).
- Reuters, 26 May 2026 — "Brazil approves first generic semaglutide pen after Ozempic patent expiry" (Anvisa approved EMS's Ozivy, Brazil's first semaglutide-based injector pen; produced at an EMS plant in São Paulo state with capacity for up to 40 million pens a year; marketing to follow approval of a price cap by Brazil's medicine pricing chamber; inclusion in the public healthcare system SUS requires Health Ministry approval; five other synthetic semaglutide applications and one biological version under review by Anvisa; Hypera planned its own generic version).
- Health and Family, 26 May 2026 — "Brazil Approves First Generic Semaglutide Pen as Ozempic Patent Expires" (Ozivy launch price reported at about 30 percent below Ozempic; Brazil's Superior Court of Justice unanimously denied Novo Nordisk's bid to extend its exclusive patent rights in February 2024, locking in the March 2026 expiry).
- World News Daily Hub, 3 November 2026 (post #699) — Dr Reddy's received tentative US Food and Drug Administration approval for generic lenacapavir, the HIV prevention drug, for 120 low- and middle-income countries (background, previously reported).
Comments
Post a Comment